Profile data is unavailable for this security.
About the company
Indoco Remedies Limited is an India-based fully integrated, research-oriented pharmaceutical company. The Company develops and manufactures a range of pharmaceutical products for the Indian and international markets. In the international market, it has tie-ups with generic companies across the globe. It has approximately eight domestic marketing divisions, with a brand portfolio in various therapeutic segments including gastro-intestinal, respiratory, anti-infective, stomatologicals, ophthalmic, nutritionals, cardiovascular, anti-diabetics, pain management, gynecology and others. The Company's brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Aloja, Glychek, Kidodent, Subitral and Rexidin. The Company has around 11 manufacturing facilities, seven for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs), supported by a research and development center and a clinical research organization facility.
- Revenue in INR (TTM)17.73bn
- Net income in INR320.40m
- Incorporated1947
- Employees5.93k
- LocationIndoco Remedies Ltd166 Indoco HouseCst Road, Santacruz EastMUMBAI 400098IndiaIND
- Phone+91 2 226541851
- Fax+91 2 226523980
- Websitehttps://www.indoco.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Syncom Formulations (India) Ltd | 3.29bn | 331.47m | 18.41bn | 802.00 | 48.23 | 5.87 | 47.82 | 5.59 | 0.406 | 0.406 | 3.49 | 3.34 | 0.8485 | 6.21 | 3.62 | 4,105,761.00 | 8.54 | 7.50 | 10.99 | 10.23 | 38.49 | 34.10 | 10.07 | 9.38 | 4.09 | 12.05 | 0.0435 | -- | 17.45 | 7.12 | 26.13 | 17.95 | -- | -- |
| Amrutanjan Health Care Ltd | 4.38bn | 475.20m | 20.31bn | 635.00 | 42.79 | 6.82 | 37.70 | 4.64 | 16.43 | 16.43 | 151.37 | 103.00 | 1.19 | 6.89 | 12.85 | 6,893,025.00 | 12.88 | 16.22 | 16.48 | 20.12 | 50.03 | 53.09 | 10.86 | 13.23 | 3.62 | 217.88 | 0.0074 | 18.95 | 10.96 | 10.71 | 12.90 | 12.46 | 26.93 | 16.43 |
| IOL Chemicals and Pharmaceuticals Ltd. | 20.72bn | 1.19bn | 20.71bn | 2.78k | 17.47 | -- | 11.20 | 0.9997 | 20.20 | 20.20 | 353.05 | -- | -- | -- | -- | 7,461,253.00 | -- | 14.91 | -- | 19.45 | 33.96 | 34.54 | 5.72 | 12.00 | -- | 10.06 | -- | 10.59 | -3.80 | 4.82 | -3.39 | -10.70 | 35.27 | -- |
| SMS Pharmaceuticals Ltd | 7.68bn | 593.38m | 20.83bn | 1.20k | 35.01 | 3.70 | 22.77 | 2.71 | 7.03 | 7.03 | 91.03 | 66.57 | 0.7278 | 1.81 | 4.18 | 6,420,048.00 | 5.55 | 5.43 | 8.40 | 7.33 | 30.10 | 33.30 | 7.62 | 7.87 | 0.7104 | 4.54 | 0.3361 | 6.17 | 35.86 | 8.81 | 805.82 | 4.47 | 8.41 | 9.86 |
| Beta Drugs Ltd | 3.35bn | 410.00m | 20.89bn | 371.00 | 50.96 | 11.55 | 40.92 | 6.24 | 42.65 | 42.65 | 348.21 | 188.13 | 1.26 | 4.04 | 3.74 | 9,022,873.00 | 15.42 | 15.10 | 23.35 | 22.23 | 39.95 | 39.77 | 12.25 | 12.38 | 1.59 | 17.06 | 0.0953 | 0.00 | 30.21 | 35.01 | 18.62 | 35.29 | -10.89 | -- |
| Windlas Biotech Ltd | 6.96bn | 612.28m | 21.77bn | 1.15k | 35.67 | 4.62 | 26.93 | 3.13 | 29.20 | 29.20 | 331.88 | 225.63 | 1.06 | 6.07 | 4.43 | 6,028,180.00 | 9.30 | -- | 13.64 | -- | 37.52 | -- | 8.80 | -- | 1.61 | 30.61 | 0.0388 | -- | 22.97 | -- | 36.51 | -- | -- | -- |
| Hester Biosciences Ltd | 3.12bn | 234.69m | 22.51bn | 642.00 | 93.25 | 7.46 | 53.44 | 7.21 | 28.37 | 28.37 | 368.62 | 354.81 | 0.4617 | 1.22 | 3.23 | 4,862,882.00 | 3.89 | 6.15 | 4.91 | 7.69 | 71.13 | 66.64 | 8.42 | 12.83 | 1.22 | 2.85 | 0.4371 | 23.27 | 14.45 | 11.33 | -29.06 | -14.59 | 1.49 | -11.42 |
| Panacea Biotec Ltd | 5.50bn | -148.63m | 26.11bn | 1.15k | -- | 3.13 | 130.75 | 4.75 | -2.46 | -2.46 | 90.20 | 135.98 | 0.4374 | 1.10 | 7.87 | 4,799,546.00 | -1.22 | 10.26 | -1.65 | 16.53 | 63.28 | 50.27 | -2.79 | 24.87 | 1.03 | -13.78 | 0.0254 | 0.00 | 21.57 | 4.13 | 96.47 | -- | 74.65 | -- |
| Themis Medicare Ltd | 4.20bn | 529.90m | 27.15bn | 1.54k | 51.29 | 6.59 | 42.43 | 6.46 | 5.75 | 5.75 | 45.63 | 44.76 | 0.7306 | 2.39 | 2.22 | 2,727,670.00 | 9.21 | 11.12 | 12.57 | 16.46 | 64.64 | 60.32 | 12.61 | 14.96 | 1.56 | -- | 0.1651 | 7.59 | 7.74 | 15.75 | -23.51 | -- | 26.73 | -- |
| Indoco Remedies Ltd | 17.73bn | 320.40m | 29.69bn | 5.93k | 96.57 | 2.73 | 21.78 | 1.67 | 3.34 | 3.34 | 175.26 | 118.23 | 0.8194 | 1.52 | 4.51 | 2,989,727.00 | 1.36 | 6.88 | 1.99 | 9.85 | 68.34 | 65.59 | 1.66 | 6.93 | 0.8142 | 1.71 | 0.4339 | 14.02 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| RPG Life Sciences Limited | 6.18bn | 706.60m | 33.16bn | 1.27k | 46.93 | 8.74 | 36.89 | 5.36 | 42.72 | 42.72 | 373.86 | 229.38 | 1.22 | 1.99 | 8.44 | 4,868,662.00 | 13.92 | 16.07 | 19.35 | 21.77 | 67.85 | 62.99 | 11.43 | 11.99 | 1.45 | 207.32 | 0.00 | 29.27 | 13.50 | 12.01 | 29.60 | 51.98 | 28.60 | 46.14 |
| Dishman Carbogen Amcis Ltd | 26.19bn | -1.74bn | 36.34bn | 1.13k | -- | 0.6335 | 41.15 | 1.39 | -11.09 | -11.09 | 166.94 | 365.90 | 0.2661 | 0.6339 | 4.45 | 23,132,690.00 | -1.77 | -0.3986 | -2.21 | -0.4888 | 78.75 | 73.83 | -6.65 | -1.54 | 0.6001 | -0.0583 | 0.3041 | -- | 8.41 | 4.91 | -414.93 | -- | -0.3175 | -- |
| Morepen Laboratories Ltd | 17.61bn | 1.31bn | 40.58bn | 1.62k | 29.15 | 3.65 | 25.78 | 2.30 | 2.54 | 2.54 | 34.07 | 20.27 | 1.28 | 4.21 | 6.02 | 10,847,620.00 | 9.56 | 7.90 | 13.28 | 13.34 | 38.57 | 33.34 | 7.48 | 5.49 | 1.99 | 31.88 | 0.0293 | 0.00 | 19.25 | 17.08 | 148.63 | 27.22 | 47.03 | -- |
| Aarti Drugs Ltd | 23.80bn | 1.52bn | 41.35bn | 1.06k | 27.26 | 3.24 | 20.12 | 1.74 | 16.62 | 16.62 | 259.74 | 139.96 | 0.9954 | 3.16 | 3.43 | 22,364,630.00 | 6.37 | 9.73 | 9.62 | 15.78 | 34.60 | 22.23 | 6.40 | 8.25 | 1.01 | 6.83 | 0.3159 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
Data as of Nov 26 2024. Currency figures normalised to Indoco Remedies Ltd's reporting currency: Indian Rupee INR
18.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 4.43m | 4.81% |
| quant Money Managers Ltd.as of 31 Oct 2024 | 4.20m | 4.56% |
| DSP Asset Managers Pvt. Ltd.as of 31 Oct 2024 | 2.91m | 3.16% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 1.54m | 1.67% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 31 Oct 2024 | 1.36m | 1.48% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 2024 | 734.53k | 0.80% |
| Tata Asset Management Pvt Ltd.as of 31 Oct 2024 | 666.99k | 0.72% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 628.94k | 0.68% |
| Fiduciary Management, Inc.as of 31 Aug 2024 | 165.42k | 0.18% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 22.75k | 0.03% |
More ▼
Data from 30 Sep 2024 - 21 Nov 2024Source: FactSet Research Systems Inc.
